strain brighton atcc vr (ATCC)
Structured Review
Strain Brighton Atcc Vr, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 70 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/atcc+strain+vr/Cowpox+virus/pm42132395-56-2-4
Average 94 stars, based on 70 article reviews
Images
Related Articles
Virus:Article Title: Article Snippet: Organism HSV-1 Reagent Result HSV-2 Reagent Result Herpes Viruses Herpes simplex virus type 1; ATCC VR733/735 - Clinical isolates (8) + - Herpes simplex virus type 2; ATCC VR734 - Clinical isolates(7) - + Varicella zoster virus; Oka strain - - Cytomegalovirus; Clinical isolate 70-35 - - Human herpes virus 6; strain Z-29 - - Epstein-Barr virus; Human Lymph. .. P3HR1 - - Other viruses Adenovirus; CDC strains V5002 - - Influenza A; Clinical isolate - - Influenza B Clinical isolate - - Mumps; CDC V5004 - - Parainfluenza 1; CDC V6004 - - Parainfluenza 2; CDC V7003 - - Parainfluenza 3; CDC V5003 - - Parainfluenza 4; Bacteria:Article Title: Article Snippet: Organism HSV-1 Reagent Result HSV-2 Reagent Result Herpes Viruses Herpes simplex virus type 1; ATCC VR733/735 - Clinical isolates (8) + - Herpes simplex virus type 2; ATCC VR734 - Clinical isolates(7) - + Varicella zoster virus; Oka strain - - Cytomegalovirus; Clinical isolate 70-35 - - Human herpes virus 6; strain Z-29 - - Epstein-Barr virus; Human Lymph. .. P3HR1 - - Other viruses Adenovirus; CDC strains V5002 - - Influenza A; Clinical isolate - - Influenza B Clinical isolate - - Mumps; CDC V5004 - - Parainfluenza 1; CDC V6004 - - Parainfluenza 2; CDC V7003 - - Parainfluenza 3; CDC V5003 - - Parainfluenza 4; Control:Article Title: Molecular detection of HPV, EBV, and polyomaviruses in thyroid tumors and their clinicopathological relevance Article Snippet: For EBV, we used established positive controls from the American Type Culture Collection (ATCC). .. The EBV control was the |
![Identification of host factors involved in SARS-CoV-2 <t>and</t> <t>HCoV-229E</t> replication (A) Schematic overview of the siRNA screening. HEK293 A/T cells were seeded in 24-well plates and transfected twice with siRNAs targeting 91 host genes previously identified as being involved in influenza virus replication. Cells were then infected with SARS-CoV-2 (100 plaque-forming unit [PFU]/100 μL) one day after the second transfection. Supernatants were collected at 2 days post-infection (dpi) and titrated by plaque assay. (B) Results of the SARS-CoV-2 siRNA screen. The 91 host factors were divided into four batches, each including a non-targeting siRNA as a negative control (N) and siRNA targeting SARS-CoV-2 nsp12 as a positive control (P). Viral titers were calculated based on the difference between each siRNA and its corresponding negative control. Each dot represents the mean of duplicate wells from a single independent experiment. Data are presented as the mean ± standard deviation (SD) of at least three independent experiments. (C) The seven host factors identified in the SARS-CoV-2 siRNA screen were further examined in HCoV-229E, along with the negative control siRNA (N) and positive control siRNA (P) targeting the HCoV-229E N gene. Following the same method described in (A), MRC-5 cells were infected with HCoV-229E (50 tissue culture infectious dose (TCID 50 )/100 μL). Supernatants were collected at 3 dpi and titrated by TCID 50 assay. Viral titers were calculated based on the difference between each siRNA and the negative control. Each dot represents the mean of duplicate wells from a single independent experiment. Data are presented as the mean ± SD of three independent experiments. (D) Cell viability was measured in duplicate wells across two independent experiments using CellTiter-Glo following siRNA transfection. See also and .](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_0041/pmc12930041/pmc12930041__gr1.jpg)